Search results for: hip OA

ACR Advocates Against Payer Mandates on Specialty Pharmacy Acquisition of In-Office Treatments

From the College | March 23, 2020

In partnership with rheumatology and other specialty organizations, the ACR is working against payer and employer policies that mandate specialty pharmacy acquisition of in-office treatments.

Enemy at the Gates: The Emerging Threat of COVID-19

Philip Seo, MD, MHS | March 23, 2020

On Dec. 30, 2019, an ophthalmologist named Li Wenliang notified his colleagues about an illness that was reminiscent of severe acute respiratory syndrome (SARS) in a city in the Hubei province of China called Wuhan. As an ophthalmologist, this was not directly relevant to his practice; he merely wanted to warn colleagues that they might…

Texas Society & Meeting Provide Professional Value, Advocacy Vision

Kimberly Retzlaff | March 20, 2020

Hundreds of physicians and practice managers gathered Feb. 28–Mar. 1 in Houston at the annual meeting of the State of Texas Association of Rheumatologists to hear clinical updates, obtain practice management tips and get to know their peers.

The Doctor Will See You Now: Legal & Regulatory Reforms Expand Telemedicine

Steven M. Harris, Esq. | March 17, 2020

In this time of COVID-19, you may be considering ways to deliver routine rheumatologic care via some form of telemedicine. Here are some of the legal considerations.

Statins Linked to Reduced Likelihood of Joint Replacement

Reuters Staff | March 16, 2020

NEW YORK (Reuters Health)—High-intensity statins are associated with a lower risk of joint replacement, new findings show. “Statins at high intensity may reduce the risk of hip and knee replacement. The effect may be RA specific,” Dr. Aliya Sarmanova of the University of Nottingham, U.K., and colleagues write in Rheumatology.1 Statins have anti-inflammatory effects, and…

Strong Support for Treat-to-Target Strategy in RA Patients

Megan Brooks | March 16, 2020

NEW YORK (Reuters Health)—In daily clinical practice, following a treat-to-target (T2T) strategy in patients with rheumatoid arthritis (RA) leads to higher rates of remission compared with not following a T2T strategy, according to a longitudinal analysis of real world data. “The results of the analysis provide direct evidence that following T2T, and particularly sustained T2T,…

Don’t Forget the Host: COVID-19 Cytokine Storm

Randy Q. Cron, MD, PhD, & W. Winn Chatham, MD | March 16, 2020

The new coronavirus outbreak, COVID-19, reminds us how we have struggled to keep ahead of mutating pathogens through the ages.

Winter 2020’s Awards, Appointments & Announcements in Rheumatology

Gretchen Henkel | March 12, 2020

2019 Lupus Foundation of America Gary S. Gilkeson Career Development Awards Emily Smitherman, MD, assistant professor, pediatric rheumatology, University of Alabama at Birmingham, and Children’s of Alabama, one of four recipients of the Gary S. Gilkeson Career Development Awards, is interested in identifying predictors for differences in disease activity within the pediatric population. To accomplish…

Harnessing Genomics in the Rare Diseases Realm

Thomas R. Collins | March 12, 2020

ATLANTA—The increasing ease and the lowering cost of genome and exome sequencing make discovery and diagnosis of rare diseases more feasible than ever, but hurdles still need to be cleared before the world of medicine can fully harness the power of this information boom, experts said in a session at the 2019 ACR/ARP Annual Meeting….

Premenopausal Osteoporosis Poses Special Clinical Challenges

Thomas R. Collins | March 12, 2020

ATLANTA—Osteoporosis in premenopausal women is uncommon compared with its frequency in post-menopausal women, but when it is suspected, it poses some difficult questions for clinicians: How should it be diagnosed in this understudied population? If found, should it be treated—and how? Elizabeth Shane, MD, professor of medicine at Columbia University and attending physician at New…